Hemogenyx PharmaceuticalsHOPHF 31 Current Ratio is 1.38 as of Dec. 2025, which is 58% below its 10-year median of 3.26. GuruFocus rates HOPHF with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Hemogenyx Pharmaceuticals ranks worse than 77.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hemogenyx Pharmaceuticals's current ratio for the quarter that ended in Dec. 2025 was 1.38.
Hemogenyx Pharmaceuticals has a current ratio of 1.38. It generally indicates good short-term financial strength.
The historical rank and industry rank for Hemogenyx Pharmaceuticals's Current Ratio or its related term are showing as below:
HOPHF'
s Current Ratio Range Over the Past 10 Years
Min: 0.72 Med: 3.26 Max: 20.22
Current: 1.38
During the past 11 years, Hemogenyx Pharmaceuticals's highest Current Ratio was 20.22. The lowest was 0.72. And the median was 3.26.
HOPHF's Current Ratio is ranked worse than 77.64% of 1409
companies
in the Biotechnology industry
Industry Median: 3.89
vs HOPHF: 1.38
Hemogenyx Pharmaceuticals (OTCPK:HOPHF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hemogenyx Pharmaceuticals Current Ratio Related Terms
Hemogenyx Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOPHF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemogenyx Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hemogenyx Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemogenyx Pharmaceuticals (HOPHF) has a Current Ratio of 1.38 as of Dec. 2025. This is 58% below median its historical median of 3.26. Over the past decade, Hemogenyx Pharmaceuticals' Current Ratio has ranged from 0.72 to 20.22. According to the industry distribution chart, Hemogenyx Pharmaceuticals ranks #1094 out of 1409 companies in the Biotechnology industry, placing it in the top 77.6%.
Is Hemogenyx Pharmaceuticals' Current Ratio too high?
Hemogenyx Pharmaceuticals' current Current Ratio of 1.38 is 58% below median its 10-year median of 3.26. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 20.22. The Biotechnology industry median Current Ratio is 3.89. Hemogenyx Pharmaceuticals' value of 1.38 is 64.5% below this industry median. Based on the distribution chart, Hemogenyx Pharmaceuticals ranks #1094 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hemogenyx Pharmaceuticals ranks #1094 out of 1409 companies for Current Ratio. This places Hemogenyx Pharmaceuticals in the lower half of its industry. The industry median Current Ratio is 3.89. Hemogenyx Pharmaceuticals' value of 1.38 is 64.5% below this benchmark. Historically, Hemogenyx Pharmaceuticals' own Current Ratio has ranged from 0.72 to 20.22 over the past decade. While the company's 10-year median is 3.26 vs. the industry median of 3.89, Hemogenyx Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemogenyx Pharmaceuticals's current Current Ratio of 1.38 is 64.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemogenyx Pharmaceuticals's current Current Ratio is 1.38, which is 58% below median its own 10-year median of 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (HOPHF) has a current Current Ratio of 1.38. The current Current Ratio is 1.38, which is 58% below median its 10-year median of 3.26 and 64.5% below the Biotechnology industry median of 3.89. Hemogenyx Pharmaceuticals' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (HOPHF), the current Current Ratio is 1.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
31GF Score
Get the complete analysis for HOPHF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOPHF has been successfully added to your 
